Combination of a PD-1 antagonist and eribulin for treating cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10945990
APP PUB NO 20180071247A1
SERIAL NO

15554540

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MERCK SHARP & DOHME CORP126 EAST LINCOLN AVENUE RAHWAY NJ 07065

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Aktan, Gursel North Wales, US 2 10
Berrak, Erhan River Vale, US 1 10
Funahashi, Yasuhiro Tsukuba, JP 54 1667
Karantza, Vassiliki Rahway, US 2 10
Matsui, Junji Tsukuba, JP 37 840
Yuan, RuiRong Fort Lee, US 1 10

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 16, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 16, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00